Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
124.20    0.00 (0.00%)
Bid:
124.00
Ask:
124.80
Spread: 0.80 (0.645%)
Market Cap: £302.33m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Rule 2.8 Announcement

7 Apr 2025 17:22

RNS Number : 9936D
Nordic Capital XI Delta, SCSP
07 April 2025
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

THIS IS AN ANNOUNCEMENT FALLING UNDER RULE 2.8 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE").

 

For immediate release

 

07 April 2025

 

Nordic Capital XI[1]

Statement regarding PureTech Health plc ("PureTech" or the "Company")

 

Nordic Capital XI notes PureTech's recent announcement regarding a possible offer for PureTech by Nordic Capital XI. Nordic Capital XI confirms that it made a private proposal to acquire the issued, and to be issued, share capital of PureTech. The proposal was rejected by the Board of PureTech. Nordic Capital XI further confirms that it does not intend to make an offer for PureTech. Accordingly, Nordic Capital XI (and any person acting in concert with it) are bound by the restrictions under Rule 2.8 of the Code.

Nordic Capital XI reserves the right to acquire PureTech shares, subject to, and in accordance with, the Code and other applicable regulations. For the purpose of Rule 2.8 of the Code, Nordic Capital XI and any person acting in concert with Nordic Capital XI, reserve the right to announce an offer or possible offer for the Company or make or participate in an offer or possible offer for the Company (and / or take any other actions which would otherwise be restricted under Rule 2.8 of the Code) within the next six months following the date of this announcement in the following circumstances:

(i) with the agreement or recommendation of the board of directors of the Company;

(ii) following the announcement of a firm intention to make an offer for the Company by or on behalf of a third party;

(iii) following the announcement by the Company of a Rule 9 waiver proposal (as described in Note 1 of the Notes on Dispensations from Rule 9 of the Code) or a reverse takeover (as defined in the Code); and/or

(iv) where the Panel on Takeovers and Mergers has determined that there has been a material change of circumstances.

Nordic Capital Advisers[2]

Tel: +46 8 440 5050

Elin Ljung / Katarina Janerud

Morgan Stanley (Financial Adviser to Nordic Capital XI)

Tel UK: +44 (0)207 425 8000David Kitterick / Jimmy Bastock

FGS Global (PR Adviser to Nordic Capital XI)

Tel UK: +44 (0)207 251 3801Guy Lamming / Gordon Simpson / Michael Turner / Anjali Unnikrishnan

Important notices

Morgan Stanley & Co. International plc ("Morgan Stanley") which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the UK is acting as financial adviser to Nordic Capital XI and no one else in connection with the matters set out in this announcement. In connection with such matters, Morgan Stanley, its affiliates and their respective directors, officers, employees and agents will not regard any other person as their client, nor will they be responsible to any other person for providing the protections afforded to their clients or for providing advice in relation to the contents of this announcement or any other matter referred to herein.

This announcement is not intended to, and does not, constitute or form part of any offer, invitation or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of, any securities whether pursuant to this announcement or otherwise.

The distribution of this announcement in jurisdictions outside the United Kingdom may be restricted by law and therefore persons into whose possession this announcement comes should inform themselves about, and observe, such restrictions. Any failure to comply with the restrictions may constitute a violation of the securities law of any such jurisdictions.


[1] Nordic Capital Epsilon SCA, SICAV-RAIF acting through its general partner Nordic Capital Epsilon GP SARL for and on behalf of its compartment Nordic Capital Epsilon SCA, SICAV-RAIF Compartment 2.

[2] "Nordic Capital Advisors" means the non-discretionary sub-advisory entities exclusively engaged by the general partners and/or delegated portfolio managers of Nordic Capital's funds and vehicles.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
OUPUBANRVWUSRAR
Date   Source Headline
29th May 20265:00 pmRNSHolding(s) in Company
27th May 20265:30 pmRNSHolding(s) in Company
22nd May 20265:00 pmRNSHolding(s) in Company
15th May 20267:00 amRNSCorrection - Holding(s) in Company
13th May 202612:00 pmRNS-RPRTC To Showcase Deupirfenidone at ATS Conference
8th May 20267:00 amRNSHolding(s) in Company
7th May 20266:27 pmRNSHolding(s) in Company
1st May 20267:00 amRNSPureTech's Seaport Prices Upsized IPO Nasdaq: SPTX
29th Apr 20267:01 amRNSFinal Results
29th Apr 20267:00 amRNSPRTC Voluntarily Delists Nasdaq Depositary Shares
27th Apr 20266:09 pmRNSHolding(s) in Company
27th Apr 202612:05 pmRNS-RPRTC's Seaport Adds Neuropsychiatry Veteran to BOD
24th Apr 20265:58 pmRNSHolding(s) in Company
22nd Apr 202612:00 pmRNS-RPRTC's Gallop: Positive Ph1 Topline MDS & AML Data
16th Apr 20265:00 pmRNSHolding(s) in Company
16th Apr 20267:00 amRNSHolding(s) in Company
13th Apr 20267:05 amRNSNotice of Results
13th Apr 20267:00 amRNSPRTC's Seaport Files for Proposed Nasdaq IPO
1st Apr 20267:00 amRNSTotal Voting Rights
25th Mar 20266:00 pmRNS-RPRTC’s Seaport: GlyphAllo Paper Published
13th Mar 20264:35 pmRNSPDMR Notification RSU Vesting
2nd Mar 20267:00 amRNSTotal Voting Rights
25th Feb 20267:00 amRNS-RPRTC to Present at Leerink Healthcare Conference
19th Feb 20265:15 pmRNS-RPRTC's Deupirfenidone Granted FDA & EU ODD for IPF
6th Jan 202612:00 pmRNS-RPureTech to Present at the JP Morgan Conference
18th Dec 20257:00 amRNSPureTech Appoints Robert Lyne as CEO
10th Dec 20255:41 pmRNSResults of AGM on June 16, 2025 – Update Statement
10th Dec 20255:30 pmRNSHolding(s) in Company
8th Dec 20257:00 amRNS-RPRTC: Successful FDA Meeting; IPF Phase 3 in 1H26
5th Dec 20256:00 pmRNS-RPRTC's Gallop: Positive Initial Topline AML Data
18th Nov 20255:30 pmRNSHolding(s) in Company
7th Nov 20256:18 pmRNSHolding(s) in Company
3rd Nov 20252:00 pmRNS-RPRTC: New LYT-200 AML Data + Update at ASH
22nd Oct 20257:00 amRNS-RPRTC: New IPF Data Show Benefit in Older Patients
17th Oct 20255:30 pmRNSHolding(s) in Company
14th Oct 20257:00 amRNSHolding(s) in Company
10th Oct 20255:59 pmRNSHolding(s) in Company
9th Oct 20256:10 pmRNSHolding(s) in Company
1st Oct 20257:00 amRNSHolding(s) in Company
29th Sep 20257:00 amRNS-RPRTC: New IPF Data Show Switch Patients Stabilized
24th Sep 20257:00 amRNSPDMR DEALING - PURCHASE OF SHARES
23rd Sep 20255:30 pmRNSHolding(s) in Company
19th Sep 20255:52 pmRNSHolding(s) in Company
19th Sep 20257:00 amRNSHolding(s) in Company
11th Sep 202512:05 pmRNS-RPRTC's Seaport Advances 2nd Candidate Into Clinic
4th Sep 20255:30 pmRNSHolding(s) in Company
1st Sep 20257:00 amRNSTotal Voting Rights
28th Aug 20257:00 amRNSHalf-year Report
21st Aug 202512:00 pmRNS-RPureTech Showcases Differentiated IPF Strategy
18th Aug 20257:00 amRNSNotice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.